Tenderwize
Retour à la recherche

Non-exclusive agreements for medicinal products containing Nintedanib (ATC L01EX09) under an Open-House model

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Jun 30, 2027 · 306 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Abschluss nicht-exklusiver Vereinbarungen über Arzneimittel mit dem Wirkstoff Nintedanib (ATC-Code: L01EX09) im Wege eines Open-House-Modells

40/100

Score d'opportunité

Needs reviewLow complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

40 / 100

Complexité

20 / 100

Facteurs de risque

No minimum purchase quantity; actual demand is unknown and may be very low.

AOK PLUS may terminate the open house if exclusive agreements are signed; past experience suggests 8-12 months after pu...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Jun 2027
  • Supply of medicinal products containing the active substance Nintedanib (ATC code L01EX09)
  • Non-exclusive framework agreement with no minimum purchase obligation
Afficher le résumé complet

This tender (ID 232797-2026) is an Open-House model for non-exclusive agreements on medicinal products containing Nintedanib (ATC L01EX09) with the health insurance fund AOK PLUS. The procedure is open to all qualified pharmaceutical companies, with no guaranteed volume and no exclusive supply. The contract runs until 30 June 2027, with periodic submission deadlines starting 30 April 2026. No estimated value or award criteria are provided; the notice explicitly states that standard procurement rules do not apply.

Risques

No minimum purchase quantity; actual demand is unknown and may be very low.

AOK PLUS may terminate the open house if exclusive agreements are signed; past experience suggests 8-12 months after pu...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical entrepreneur as per §4 Abs. 18 AMG for the offered products
  • Must have registered office in Germany, EU, or EEA

Eligibility

  • Must submit self-declaration on absence of exclusion grounds (§§ 123, 124 GWB)

Les exigences peuvent être incomplètes.

Critères d'attribution

Lot 1

No award criteria specified (technical placeholder due to notice format).

Acheteur

Localisation

Erfurt, DEU

Profil acheteur

Ouvrir le profil

Identifiant

DE256878834

Activité

Health

Lots (1)

LOT-0001

Non-exclusive agreements for medicinal products containing Nintedanib (ATC L01EX09) under an Open-House model

Open-House model for non-exclusive agreements for the supply of Nintedanib to AOK PLUS, covering the regions of Saxony and Thuringia. No guaranteed minimum volume; delivery depends on demand. Contract end date is 30 June 2027.

SuppliesFrameworkEU fundedElectronic submission

Localisation

Dresden, Germany

Durée

May 2026 - Jun 2027

Catégorie

Pharmaceutical products

Critères d'attribution

No award criteria specified (technical placeholder due to notice format).

Détails de la procédure

Date de publication
02 Apr 2026
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
232797-2026

Documents (1)

Document de consultation 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30